No Image Available

CRT-Ps

Percepta™ CRT-P MRI SureScan™

<p>Percepta™ cardiac resynchronization therapy pacemakers (CRT-Ps) are enabled with BlueSync™ technology, allowing for tablet-based programming.</p>

Ordering information
Contact a representative

Unmatched feature suite

Enhanced longevity

The estimated longevity of the Percepta™ Quad CRT-P MRI SureScan™ is greater than that of Viva™ CRT-P.†

8.6
years

Viva™ CRT-P†,‡,1
9.9
years

Percepta™ Quad CRT-P MRI SureScan™‡,§,2,3

PhysioCurve™ design for patient comfort

  • Tapered at the head and bottom of device to reduce skin pressure and promote patient comfort
  • Designed with lead wrap in mind — landing area to minimize additional stresses on the lead4
Learn about Percepta™ CRT-Ps for heart failure management.

Exclusive algorithms to optimize cardiac resynchronization (CRT) delivery

Improvement in CRT response

12%

Improvement in CRT patient response with AdaptiveCRT™.◊,5

Reduction in hospitalizations

59%

Reduction in a patient’s odds of 30-day HF remission with AdaptivCRT™.6

Relative reduction in mortality

29%

AdaptivCRT™ is associated with a 29% relative reduction in mortality.¶,7

Exclusive algorithms to manage AF and optimize CRT delivery​

 

  • Reactive ATP™ algorithm opportunistically attempts to terminate an AF episode when the rhythm organizes and/or slows.​
  • 36% relative reduction in AT/AF episodes ≥ 7 days with Reactive ATP™ Algorithm∆1​
  • AdaptivCRT™ Algorithm adapts to patients’ changing needs by optimizing CRT pacing minute-to-minute.​
    • 16% mortality in AdaptResponse at 5 years is the lowest of any radomized CRT trial, when accounting for NYHA class.2–9
    • 93% response rate overall at 6 months, highest of any CRT trial1,10–17​
    • High percent Adaptive LV pacing associated with 24% significant reduction in mortality/HF events2​
    • 41% lower rate of device change-outs for battery depletion through 8 years with AdaptivCRT™ algorithm​2

 

Reimagined connectivity with BlueSync™ technology

Percepta™ CRT-Ps with BlueSync™ technology enable secure, wireless communication.

CareLink SmartSync™ interface shown on tablet

Tablet-based CareLink SmartSync™ device manager

Image of Percepta™ quad CRT-P MRI SureScan™ and Percepta™ CRT-P MRI SureScan™ with Bluetooth™ icon

Percepta™ CRT-Ps and
Percepta™ Quad CRT-Ps

MyCareLink Heart™ app and MyCareLink Relay™ home communicator on white background

MyCareLink Heart™ mobile app or MyCareLink Relay™ Communicator

View the Get Connected service shown on a desktop monitor.

Carelink™ network and the get connected service

Streamlined heart failure management with CareAlert™ notifications

Time to a clinical decision was about seven times faster with the use of Medtronic CareAlert™ notifications compared to standard office follow-up.10

Clinical management alerts

  • Atrial tachyarrhythmia / atrial fibrillation (AT/AF) daily burden enable 
  • Average ventricular rate during AT/AF 
  • Monitored ventricular tachyarrhythmia (VT) episode 
  • Ventricular pacing < 90%

Device management alerts 

  • Low battery voltage recommended replacement time (RRT) 
  • Atrial pacing enable  
  • Right-ventricular (RV) pacing enable   
  • Left-ventricular (LV) pacing enable  
  • Atrial capture enable  
  • RV capture enable  
  • LV capture enable

System features and exclusive algorithms

Quad models

  • BlueSync™ technology 
  • AdaptivCRT™ algorithm
  • Multiple-point pacing
  • OptiVol™ 2.0 fluid status monitoring
  • MRI SureScan™ technology
  • PhysioCurve design
  • Attain™ Performa™ advanced quadripolar lead and VectorExpress™ LV automated test

Non-quad models

  • BlueSync™ technology 
  • AdaptivCRT™ algorithm
  • OptiVol™ 2.0 fluid status monitoring
  • MRI SureScan™ technology
  • PhysioCurve design

Ordering information

Percepta™ CRT-P MRI

Item number Mass (g) Volume (mL) Size — height × width × depth (mm) Connector
W1TR01 30 19.9 59 × 46.5 × 11 3x IS-1

Percepta™ Quad CRT-P MRI

Item number Mass (g) Volume (mL) Size — height × width × depth (mm) Connector
W4TR01 30 19.5 59 × 46.5 × 11 IS-1

Similar products

The Bluetooth™ word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.

† Estimated with AdaptivCRT™ programmed to BIV and LV.

‡ Viva™ CRT-P projected service life estimates assume device configuration at 50% AP, 50% RVP, 100% LVP, 2.5 V in both A and RV, 3.0 V in LV, 500 Ω lead impedances for all three chambers, and pre-storage EGM off projected service life estimates are based on accelerated battery discharge data and device modeling. The values calculated based on this information should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.

§ Percepta™ CRT-P projected service life estimates assume device configuration at 50% AP, 50% RVP, 100% LVP, 2.5 V in A, RV, and LV, 500 Ω lead impedances for all three chambers, and prearrhythmia EGM storage programmed to on for the device lifetime. Projected service life estimates are based on accelerated battery discharge data and device modeling. The values calculated based on this information should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience. 

◊ Comparing AdaptivCRT™ to eco-optimized BiV pacing in patients with normal AV conduction, percentage of patients improved in Packer clinical composite score (CCS) at 6-month follow-up. CCS is a composite measure of mortality, HF hospitalizations, and symptomatic changes.

¶ Patients who received AdaptivCRT™ were associated with a 29% relative reduction in all-cause mortality versus conventional CRT (after adjusting for other potential risk factors including age, gender, LVEF, NYHA class, QRS duration, AF, CAD, hypertension, AV block, and LBBB).

# Most of the reduction in AF occurred in subgroups with prolonged AV conduction at baseline and with significant left atrial reverse remodeling.

∆ Compared to matched control group. 

  1. Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. July 2019;42(7):970–979.​
  2. Wilkoff BL,Filippatos, G, Leclercq C, Gold MR, Hersi AS, Kusano K, et al. Adaptive versus conventional cardiac resynchronization therapy in patients with heart failure (AdaptResponse): A global, prospective, randomised controlled trial. Lancet. 2023;402(10408):1147–57.​
  3. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–53.​
  4. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, WIlkoff B, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289(20):2685–94.​
  5. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, DeMarco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.​
  6. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.​
  7. Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and prevoius heart failure symptoms. J Am Coll Cardiol. 2008;52(23):1834–43.​
  8. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization thereapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.
  9. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385–95.​
  10. Forleo GF, Santini L, Giammaria M, Potenza D, Curnis A, Calabrese V, et al. Multipoint pacing via a quadripolar left-ventricular lead: preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy (IRON-MPP) Europace. 2017;19(7):1170–77.​
  11. Martin DO, Lemke B, Birnie D, Krum H, Lee KLF, Aonuma K, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm. 2012;9(11):1807–14.​
  12. Varma N, Auricchio A, Connolly AT, Boehmer J, Bahu M, Costanzo MR, et al. The cost of non-response to cardiac resynchromization therapy: characterizing heart failure events following cardiac resynchronizzation therapy. Europace. 2021;23(10):1586–95.​
  13. Jackson KP, Faerestrand S, Philippon F, Yee R, Kong MH, Kloppe A, et al. Performance of a novel active fixation quadripolar left ventricular lead for cardiac resynchronization therapy: Attain Stability Quad clinical study results. J Cardiovasc Electrophysiol. 2020;31(5):1147–54.​
  14. Abraham WT, León AR, St. John Sutton MG, Keteyian SJ, Fieberg AM, Chinchoy E, et al. Randomized controlled trial comparing simultaneous versus optimized sequential interventricular stimulation during cardiac resynchronization therapy. Am Heart J. 2012;164(5):735–41.​
  15. Rickard J, Gold MR, Patel D, Wilkoff BL, Varma N, Sinha S, et al. Long-term outcomes in nonprogressors to cardiac resynchronization thereapy. Heart Rhythm. 2023;20(2):165–70.​
  16. Chung ES, León AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008;117(20):2608–16.​
  17. Linde C, Abraham WT, Goldf MR, Daubert JC, Tang ASL, Young JB, et al. Predictors of short-term clinicial response to cardiac resynchronization therapy. Eur J Heart Fail. 2017;19(8):1056–63.​